Global  

Trusted News Discovery Since 2008
One News Page
One News Page > Business News > Lexaria Bioscience widens scope of pharmaceutical subsidiary in bid to develop treatment for coronavirus

Lexaria Bioscience widens scope of pharmaceutical subsidiary in bid to develop treatment for coronavirus

Proactive Investors Monday, 23 March 2020 ()
Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) told investors Monday that it has broadened the scope of its pharmaceutical subsidiary in a bid to help assist in the global fight against coronavirus. The company’s subsidiary Lexaria Pharmaceutical Corp will look at how the parent company’s DehydraTECH drug delivery platform could improve delivery and effectiveness of antiviral drugs to treat coronavirus. Kelowna, British Columbia-based Lexaria said it plans to expand collaboration with leading laboratories in North America and internationally “as soon as possible.” READ: Lexaria Bioscience initiates coronavirus drug delivery program The news comes after the company revealed last week that it has initiated a program with top labs in the United States and Canada to study the benefits of the company’s DehydraTECH drug delivery platform for boosting the delivery and effectiveness of certain antiretroviral drugs being tapped in the fight against the coronavirus. DehydraTECH enhances the way active pharmaceutical ingredients enter the bloodstream, promoting lower overall dosing and higher effectiveness for lipophilic active molecules, or those that dissolve in lipids or fats. As the coronavirus pandemic continues, researchers are currently looking at various antiviral drugs as potential candidates to treat infected patients. Many of these drugs are fat-soluble and can present significant bioavailability challenges in successfully reaching the human bloodstream when administered in oral form. Billion dollar savings DehydraTECH reduces time of onset and increases bioavailability in every fat soluble drug with which it has been tested to date, according to Lexaria. “The increase in bioavailability can significantly reduce the drug dose required to treat a condition, thereby reducing treatment costs,” the company told shareholders in a statement on Monday. “In the case of COVID-19 where many millions of drug doses may be required worldwide, this has the potential to save billions of dollars and improve accessibility to positively effect healthcare on a global scale.” Human trials The firm completed the design phase and now plans to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers with three or more antiviral drugs that have previously been studied against other coronavirus strains, comparing DehydraTECH formulations to controls, it said. If the trial data successfully demonstrates antiviral drug delivery efficiencies, Lexaria said it will provide that data to researchers around the world to enable additional practical research in utilization of similar antiviral drugs in combating coronavirus. The company also said that it has cancelled nearly 3.3 million stock options priced between US$0.37 and $1.53. It is also terminating its 2007 stock option plan as there are no longer any options issued under the plan. Contact Angela at [email protected] Follow her on Twitter @AHarmantas
0
shares
ShareTweetSavePostSend
 
Credit: WBZ CBS Boston - Published < > Embed
News video: Drug Eyed As Potential Coronavirus Treatment Being Hoarded, Leaving Patients In Need Without

Drug Eyed As Potential Coronavirus Treatment Being Hoarded, Leaving Patients In Need Without 02:06

A drug that President Donald Trump has touted as a possible treatment for coronavirus is now in short supply. WBZ-TV's Anna Meiler reports.

Recent related videos from verified sources

Coronavirus Update: Mayor Bill De Blasio Urges New Yorkers To Cover Faces In Public [Video]

Coronavirus Update: Mayor Bill De Blasio Urges New Yorkers To Cover Faces In Public

Mayor Bill de Blasio now says all New Yorkers should cover their faces when they have to go out in public.

Credit: CBS 2 New York     Duration: 00:27Published
Coronavirus Update: Javits Center Will Now Be Used To Help Treat COVID-19 Patients [Video]

Coronavirus Update: Javits Center Will Now Be Used To Help Treat COVID-19 Patients

President Donald Trump has approved Gov. Andrew Cuomo‘s request to use the Javits Center to care for COVID-19 patients.

Credit: CBS 2 New York     Duration: 00:40Published

Recent related news from verified sources

Sun Pharma's U.S. unit donates hydroxychloroquine sulfate tablets in fight against coronavirus

A subsidiary of India's Sun Pharmaceutical Industries Ltd said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets in the United States as a...
Reuters

Cardiol Therapeutics expecting significant growth in 2020 with launch of its pharmaceutical cannabidiol formulation in Canada

Cardiol Therapeutics Inc (TSE:CRDL) (OTCMKTS:CRTPF) CEO David Elsley told shareholders that the company is expecting significant growth in 2020 as it moves to...
Proactive Investors

You Might Like


Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2020 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.